GlassScriptPhysician profile
Michael P Milligan
NPI 1790776045
$3,752.57
in general payments reported to CMS, 2019-2025
25 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $400 · 2021: $731 · 2022: $776 · 2023: $581 · 2024: $554 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $642.78 | 2021-2025 | Libtayo, Dupixent |
| Amgen INC. | $421.63 | 2019-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $345.79 | 2019-2025 | |
| Genzyme Corporation | $204.24 | 2021-2023 | |
| Lilly USA, LLC | $183.28 | 2022-2025 | Ebglyss, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.65 | 2019-2020 | |
| Pfizer INC. | $154.76 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $79.86 | 2024-2025 | Ycanth |
| Leo Pharma INC. | $79.42 | 2019-2022 | |
| Celgene Corporation | $67.29 | 2019 | |
| Galderma Laboratories, L.P. | $57.75 | 2024-2025 | Aklief, Nemluvio |
| Almirall LLC | $48.74 | 2021-2022 | |
| Ucb, INC. | $43.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.79 | 2024 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.51 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.43 | 2024 | Spevigo |
| Strata Skin Sciences, INC. | $22.66 | 2024 | Xtrac |
| Sun Pharmaceutical Industries INC. | $22.45 | 2021 | |
| Janssen Biotech, INC. | $21.62 | 2022 | |
| Incyte Corporation | $21.44 | 2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $20.29 | 2020 | |
| Kyowa Kirin, INC. | $19.79 | 2024 | Poteligeo |
| Dermavant Sciences, INC. | $15.19 | 2023 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.